Drug details

Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)

type of CAR-T Cell Therapies

Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous T cell immunotherapy used to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

The following drugs are related to Breyanzi, either as a replacement or used together:

• Calquence (acalabrutinib capsules)
• Adcetris (brentuximab vedotin)
• Aliqopa (copanlisib for injection, for intravenous use)
• Arranon (nelarabine)
• YESCARTA (axicabtagene ciloleucel suspension for intravenous infusion)
• Beleodaq (belinostat for injection for intravenous use)
• Bendeka (bendamustine hydrochloride injection)
• Brukinsa (zanubrutinib capsules)
• Xalkori (crizotinib)
• Epkinly (epcoritamab-bysp injection)
• Folotyn (pralatrexate solution for intravenous injection)
• Gazyva (obinutuzumab injection)
• Zevalin (ibritumomab tiuxetan)
• Zydelig (idelalisib tablets)
• Keytruda (pembrolizumab for injection)
• Kymriah (tisagenlecleucel suspension for intravenous infusion)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Lunsumio (mosunetuzumab-axgb injection)
• Poteligeo (mogamulizumab-kpkc injection)
• Monjuvi (tafasitamab-cxix injection)
• Mozobil (plerixafor injection)
• Polivy (polatuzumab vedotin-piiq for injection)
• Truxima (rituximab-abbs injection)
• Xpovio (selinexor tablets)
• Tazverik (tazemetostat tablets)
• Zolinza (vorinostat)